## India Equity Research | Consumer Goods May 22, 2020 **Result Update**

# **Colgate-Palmolive**

Refer to important disclosures at the end of this report

# Aggressive approach to help gain market share

CMP: Rs 1,335 as of (May 22, 2020) TP: Rs 1,500 (▲) 12 months Rating: BUY (=)

Upside: 12.4 %

- Colgate's Q4FY20 performance was weak. EBITDA/adj. PAT fell 15%/5%, higher than expected. Revenue was down 7%, while volume declined 8% - both in line and largely impacted by the Covid-19-led disruption in March end.
- Growth trends were better in Jan-Feb before weakening in March end. After a slight decline in 2019, market shares saw a pick-up in the Mar'20 quarter, with an 80bps MoM improvement in March, which is positive.
- Colgate seems more aggressive and agile now, with stronger innovations, continued ad spends behind the core during disruptions and faster ramp-up in distribution (including ecommerce), which should help gain shares over peers, in our view.
- In addition, Colgate's portfolio offers steady visibility and is likely to be more resilient and less affected by the shifts in consumption post the disruption. Maintain Buy, with a revised TP of Rs1,500 (from Rs1,450) based on 40x Jun-22 EPS.

**In-line sales performance, Covid-19 disruption impacts volumes:** Colgate's revenue declined 7%, while volume fell 8% - largely in-line with our estimates – dragged by the Covid-19-led disruptions in supplies in the second half of March, excluding which growth was healthy during Jan-Feb period as per management. Market shares for 2019 were slightly lower, but recent trends are improving with MoM shares up 80bps in March, which is positive. Colgate seems more aggressive and agile now, with stronger innovations and faster ramp-up in distribution, which should help it gain shares over peers.

**Margins contract due to higher employee costs; outlook remains positive:** Gross margins expanded by 10bps but EBITDA fell 15%, with margins down 240bps due to a 22% increase in employee costs (including one-off costs) and flat ad spends (14.6% of sales vs. 13.6% in Q4FY19), which was marginally offset by the decrease in other overhead costs. Benign input inflation, cost savings and reduced competitive activity are likely to drive further improvement in margins ahead. Excluding the impact of prior tax reversals, adjusted PAT declined 5%, aided by higher other income, partly driven by one-off gains from reversal of provisions.

**Portfolio likely to be steady and resilient; retain Buy:** Colgate's portfolio offers steady visibility as the oral care is likely to be more resilient and less affected by the shifts in consumption post the disruption. Increased aggression in the oral care along with a cautious expansion of portfolio keeps us positive. We estimate a sales/earnings CAGR of 7%/11% over FY20-22. Maintain Buy / OW in EAP, with a revised TP of Rs1,500 (from Rs1,450) based on 40x Jun-22 EPS.

Please see our sector model portfolio (Emkay Alpha Portfolio): Consumer Goods & Retail (page 8)

## Financial Snapshot (Standalone)

	,				
(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	44,624	45,251	47,042	51,661	56,814
EBITDA	12,361	12,017	13,022	14,601	16,227
EBITDA Margin (%)	27.7	26.6	27.7	28.3	28.6
APAT	7,451	8,165	8,483	9,665	10,819
EPS (Rs)	27.4	30.0	31.2	35.5	39.8
EPS (% chg)	8.8	9.6	3.9	13.9	11.9
ROE (%)	50.1	55.4	55.9	61.6	64.9
P/E (x)	48.7	44.5	42.8	37.6	33.6
EV/EBITDA (x)	29.1	30.0	27.6	24.5	21.9
P/BV (x)	25.1	24.2	23.7	22.7	21.0

Source: Company, Emkay Research



# Change in Estimates

	21E/F)	(22E (9	%)	1.6/0.5				
Target Price	change	e (%)		3.4				
Target Period	d (Mon	ths)		12				
Previous Rec	:0			BUY				
Emkay vs Co	onsen	sus						
	EPS E	stimat						
		F	Y21E	FY22E				
Emkay			31.2	35.5				
Consensus			32.6	36.2				
Mean Conser	nsus T	P (12N	1)	Rs 1,390				
Stock Details								
Bloomberg C				CLGT IN				
Face Value (	Rs)			1				
Shares outsta	anding	(mn)		272				
52 Week H/L 1,643 / 1,065								
M Cap (Rs bn/USD bn) 363 / 4.80								
Daily Avg Volume (nos.) 9,71,381								
Daily Avg Tu	rnover	(US\$ r	nn)	17.1				
Shareholding Pattern Mar '20								
	g		ai 20					
Promoters	9		ai 20	51.0%				
	9		1 20	51.0% 16.2%				
Promoters	<u> </u>							
Promoters FIIs				16.2%				
Promoters FIIs DIIs	thers			16.2% 10.0%				
Promoters FIIs DIIs Public and O	thers		6M	16.2% 10.0% 22.8%				
Promoters FIIs DIIs Public and O Price Perform	thers	)		16.2% 10.0% 22.8% <b>12M</b>				
Promoters FIIs DIIs Public and Or <b>Price Perform</b> (%)	thers mance 1M	e 3M	6M	16.2% 10.0% 22.8% <b>12M</b> 16				
Promoters FIIs DIIs Public and O Price Perform (%) Absolute Rel. to Nifty	thers mance 1M (5) (6)	9 3M (1) 32	<b>6M</b> (12)	16.2% 10.0% 22.8% <b>12M</b> 16				
Promoters FIIs DIIs Public and O Price Perform (%) Absolute Rel. to Nifty Relative price	thers mance 1M (5) (6)	9 3M (1) 32	<b>6M</b> (12)	16.2% 10.0% 22.8% <b>12M</b> 16				
Promoters FIIs DIIs Public and O Price Perform (%) Absolute Rel. to Nifty	thers mance 1M (5) (6)	9 3M (1) 32	<b>6M</b> (12)	16.2% 10.0% 22.8% <b>12M</b> 16				
Promoters FIIs DIIs Public and O Price Perform (%) Absolute Rel. to Nifty Relative price 1625 1510	thers mance 1M (5) (6)	9 3M (1) 32	<b>6M</b> (12)	$ \begin{array}{c} 16.2\% \\ 10.0\% \\ 22.8\% \\ \hline 12M \\ 16 \\ 49 \\ \hline & 49 \\ \hline & 62 \\ \end{array} $				
Promoters FIIs DIIs Public and O Price Perform (%) Absolute Rel. to Nifty Relative price 1625 Rs	thers mance 1M (5) (6)	9 3M (1) 32	<b>6M</b> (12)	16.2% 10.0% 22.8% 12M 16 49				
Promoters FIIs DIIs Public and O Price Perform (%) Absolute Rel. to Nifty Relative price 1625 1510	thers mance 1M (5) (6)	9 3M (1) 32	<b>6M</b> (12)	$ \begin{array}{c} 16.2\% \\ 10.0\% \\ 22.8\% \\ \hline 12M \\ 16 \\ 49 \\ \hline & 49 \\ \hline & 62 \\ \end{array} $				
Promoters FIIs DIIs Public and O Price Perform (%) Absolute Rel. to Nifty Relative price 1625 Rs 1510 - 1395 -	thers mance 1M (5) (6)	9 3M (1) 32	<b>6M</b> (12)	16.2% 10.0% 22.8% 12M 16 49 % 62 44				

 May-19 Jul-19 Sep-19Nov-19Jan-20 Mar-20May-20

 Colgate-Palmolive (LHS)
 Rel to Nifty (RHS)

Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:


#### Ashit Desai

ashit.desai@emkayglobal.com +91 22 6612 1340

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.


# **Story in Charts**

#### Exhibit 1: Volume decline due to Covid-19 related supply issues



Source: Company, Emkay Research


#### Exhibit 3: A&P investments remain flat, despite lower sales




Source: Company, Emkay Research


#### Exhibit 5: Market share improvement in modern trade

Winning in Modern Trade




Source: Company, Emkay Research






#### Exhibit 4: Ramp up in Ecom before Covid-19 driving share gains



Source: Company, Emkay Research

#### Exhibit 6: One-year forward P/E band chart



# Exhibit 7: Actual vs. Estimates (Q4FY20)

Rs mn	Actual	Estimate		% variation		Comment
KS IIII	Actual	Emkay	Consensus	Emkay	Consensus	Comment
Revenues	10,713	10,868	11,395	-1.4%	-6.0%	In-line revenue; volumes decline of 8%
EBITDA	2,629	2,892	3,075	-9.1%	-14.5%	
EBITDA Margin (%)	24.5%	26.6%	27.0%	-207	-245	Margins impacted by 22% increase in employee costs
APAT	1,732	1,798	1,976	-3.7%	-12.3%	

Source: Company, Emkay Research

## Exhibit 8: Quarterly Performance (Standalone)

Y/E, Mar (Rs. mn)	4QFY19	1QFY20	2QFY20	3QFY20	4QFY20	YoY (%)	QoQ (%)	FY19	FY20	YoY (%)
Revenue	11,538	10,849	12,218	11,472	10,713	-7.1	-6.6	44,624	45,251	1.4
Expenditure	8,433	7,851	8,988	8,311	8,084	-4.1	-2.7	32,264	33,234	3.0
Consumption of RM	4,088	3,704	4,308	3,931	3,786	-7.4	-3.7	15,586	15,729	0.9
as % of sales	35.4%	34.1%	35.3%	34.3%	35.3%			34.9%	34.8%	
Employee Cost	735	835	819	770	899	22.3	16.7	2,959	3,323	12.3
as % of sales	6.4%	7.7%	6.7%	6.7%	8.4%			6.6%	7.3%	
Advertising & SP	1,563	1,513	1,758	1,434	1,555	-0.5	8.4	5,647	6,260	10.9
as % of sales	13.5%	13.9%	14.4%	12.5%	14.5%			12.7%	13.8%	
Other expenditure	2,048	1,799	2,104	2,176	1,844	-9.9	-15.3	8,072	7,922	-1.9
as % of sales	17.7%	16.6%	17.2%	19.0%	17.2%			18.1%	17.5%	
EBITDA	3,104	2,998	3,230	3,161	2,629	-15.3	-16.8	12,361	12,017	-2.8
Depreciation	394	499	504	515	462	17.3	-10.3	1,592	1,979	24.4
EBIT	2,711	2,500	2,726	2,646	2,167	-20.1	-18.1	10,769	10,038	-6.8
Other Income	120	152	86	58	196	64.4	238.6	377	492	30.7
Interest cost	25	23	24	29	20			25	96	
Exceptional items	-36	0	0	0	0			305	0	
PBT	2,769	2,628	2,788	2,674	2,344	-15.4	-12.4	11,426	10,434	-8.7
Total Tax	793	937	347	683	302	-61.9	-55.8	3,670	2,269	-38.2
Reported PAT	1,976	1,691	2,441	1,991	2,042	3.3	2.5	7,756	8,165	5.3
Extra ordinary items	-161	0	0	-0	0			-632	-310	
Adjusted PAT	1,815	1,691	2,441	1,991	1732	-4.6	-13.1	7,124	7,855	10.3
Adjusted EPS	6.7	6.2	9.0	7.3	6.4	-4.6	-13.1	26.2	28.9	10.3
Margins (%)						(bps)	(bps)			(bps)
Gross Margin	64.6	65.9	64.7	65.7	64.7	10	-110	65.1	65.2	20
EBIDTA	26.9	27.6	26.4	27.6	24.5	-240	-300	27.7	26.6	-110
EBIT	23.5	23.0	20.4	23.1	24.3	-330	-280	24.1	20.0	-200
EBT	23.0	23.0	22.3	23.1	20.2	-210	-200	24.1	23.1	-250
PAT	15.7	15.6	22.0	17.4	16.3	-210 60	-140	16.0	17.4	140
Effective Tax rate	28.6	35.7	12.4	25.6	12.9	-1,580	-1,270	32.1	21.7	-1,040

# Exhibit 9: Revision in Earnings

	FY21E				FY23E		
Y/E, Mar (Rs. mn)	Earlier	Revised	% Change	Earlier	Revised	% Change	Introduced
Revenues	46,939	46,648	-0.6	52,239	51,248	-1.9	56,380
EBITDA	13,016	13,022	0.0	14,747	14,601	-1.0	16,227
EBITDA Margin (%)	27.7	27.9	20 bps	28.2	28.5	30 bps	28.8
APAT	8,351	8,483	1.6	9,616	9,665	0.5	10,819
EPS	30.7	31.2	1.6	35.4	35.5	0.5	39.8

Source: Company, Emkay Research

# Exhibit 10: Revenue Assumptions

	FY19	FY20	FY21E	FY22E	FY23E
Toothpaste Volume Growth	5%	1%	3%	6%	6%
Toothpaste Realization growth	2%	1%	1%	4%	4%
Revenue (Rs mn)	44,624	45,251	47,042	51,661	56,814
Growth	7%	1%	4%	10%	10%

Source: Company, Emkay Research

# **Exhibit 11: Relative Valuation**

Commonies	Price	Мсар	Deee	Reco Price		EPS (Rs)			P/E (x)		EV / EBITDA (x)		
Companies	(Rs)	(Rs bn)	Reco	(Rs)	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E	FY20E	FY21E	FY22E
Asian Paints	1,574	1,510	Hold	1,650	28.6	34.2	39.1	55.1	46.0	40.3	35.1	29.4	25.8
Berger Paints	465	452	Sell	430	6.9	8.7	10.1	67.4	53.4	46.1	41.9	33.6	29.0
Britannia	3,111	748	Buy	3,250	56.9	61.3	70.5	54.7	50.7	44.1	40.3	36.8	31.9
Colgate	1,335	363	Buy	1,500	30.0	31.2	35.5	44.5	42.8	37.6	30.0	27.6	24.5
Dabur	440	778	Hold	465	9.1	10.2	11.6	48.5	43.3	38.1	39.9	35.4	30.1
Emami	210	95	Hold	240	11.5	11.3	11.9	18.1	18.6	17.6	12.5	12.2	11.3
GCPL	576	588	Hold	600	13.8	15.6	17.6	41.6	36.9	32.7	28.3	25.5	22.8
HUL	1,971	4,627	Hold	2,300	31.2	35.7	42.0	63.2	55.1	46.9	47.6	41.9	35.9
ITC	189	2,323	Buy	240	11.7	12.1	13.4	16.2	15.6	14.1	11.7	11.0	9.7
Marico	317	409	Hold	320	8.3	8.5	9.5	38.1	37.1	33.4	27.2	25.8	23.3
Nestle	16,289	1,570	Sell	15,000	206.8	235.7	275.9	78.8	69.1	59.0	54.8	49.2	42.4
Pidilite	1,419	721	Sell	1,170	22.7	25.2	29.2	62.6	56.4	48.6	46.1	41.7	35.9
Radico Khaitan	306	41	Buy	400	15.8	17.5	22.1	19.3	17.5	13.8	12.1	11.0	8.8
United Breweries	927	245	Buy	1,230	17.0	20.4	27.0	54.5	45.5	34.4	27.3	23.4	18.7
United Spirits	610	443	Buy	660	11.9	13.0	16.5	51.3	47.0	37.0	30.5	28.4	23.3

# Key Financials (Standalone)

# Income Statement

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	44,624	45,251	47,042	51,661	56,814
Expenditure	32,264	33,234	34,020	37,061	40,588
EBITDA	12,361	12,017	13,022	14,601	16,227
Depreciation	1,592	1,979	2,042	2,116	2,287
EBIT	10,769	10,038	10,980	12,485	13,939
Other Income	377	492	522	605	702
Interest expenses	25	96	100	100	100
РВТ	11,121	10,434	11,402	12,991	14,542
Тах	3,670	2,269	2,919	3,326	3,723
Extraordinary Items	305	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	7,756	8,165	8,483	9,665	10,819
Adjusted PAT	7,451	8,165	8,483	9,665	10,819

# Balance Sheet

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	272	272	272	272	272
Reserves & surplus	14,196	14,744	15,067	15,756	17,055
Net worth	14,468	15,016	15,339	16,028	17,327
Minority Interest	0	0	0	0	0
Loan Funds	777	0	0	0	0
Net deferred tax liability	(686)	(1,430)	(1,430)	(1,430)	(1,430)
Total Liabilities	14,558	13,586	13,909	14,598	15,897
Net block	11,909	11,229	10,487	10,072	9,484
Investment	312	186	186	186	186
Current Assets	10,555	8,709	10,366	11,870	14,713
Cash & bank balance	3,994	2,449	3,792	5,095	7,419
Other Current Assets	801	812	833	853	903
Current liabilities & Provision	10,203	8,438	9,030	9,430	10,386
Net current assets	351	271	1,336	2,440	4,327
Misc. exp	0	0	0	0	0
Total Assets	14,558	13,586	13,909	14,598	15,897

# Cash Flow

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	10,744	9,941	10,880	12,385	13,839
Other Non-Cash items	0	0	0	0	0
Chg in working cap	284	(2,208)	279	198	438
Operating Cashflow	9,656	8,032	10,904	12,079	13,644
Capital expenditure	(2,442)	(1,213)	(1,300)	(1,700)	(1,700)
Free Cash Flow	7,214	6,819	9,604	10,379	11,944
Investments	0	125	0	0	0
Other Investing Cash Flow	(377)	(492)	(522)	(605)	(702)
Investing Cashflow	(2,442)	(1,088)	(1,300)	(1,700)	(1,700)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	777	(777)	0	0	0
Dividend paid (incl tax)	(7,509)	(7,616)	(8,160)	(8,976)	(9,520)
Other Financing Cash Flow	(1,025)	0	0	0	0
Financing Cashflow	(7,782)	(8,489)	(8,260)	(9,076)	(9,620)
Net chg in cash	(568)	(1,545)	1,344	1,303	2,324
Opening cash position	4,562	3,994	2,449	3,792	5,095
Closing cash position	3,994	2,449	3,792	5,095	7,419

Profitability (%)	FY19	FY20	FY21E	FY22E	FY23E
EBITDA Margin	27.7	26.6	27.7	28.3	28.6
EBIT Margin	24.1	22.2	23.3	24.2	24.5
Effective Tax Rate	33.0	21.7	25.6	25.6	25.6
Net Margin	16.7	18.0	18.0	18.7	19.0
ROCE	75.3	74.8	83.7	91.8	96.0
ROE	50.1	55.4	55.9	61.6	64.9
RoIC	127.7	115.9	128.6	161.6	201.9
Per Share Data (Rs)	FY19	FY20	FY21E	FY22E	FY23E
EPS	27.4	30.0	31.2	35.5	39.8
CEPS	33.2	37.3	38.7	43.3	48.2
BVPS	53.2	55.2	56.4	58.9	63.7
DPS	23.0	28.0	30.0	33.0	35.0
Network (A)	5)/40	51/00	EV04 E	EVOOE	
Valuations (x) PER	FY19	FY20	FY21E	FY22E	FY23E
	48.7 40.2	44.5	42.8	37.6	33.6
P/CEPS P/BV	40.2 25.1	35.8 24.2	34.5 23.7	30.8 22.7	27.7 21.(
EV / Sales	25.1	24.2 8.0	23.7	7.0	21.0
EV / EBITDA	29.1	30.0			21.9
			27.6	24.5	
Dividend Yield (%)	1.7	2.1	2.2	2.5	2.6
Gearing Ratio (x)	FY19	FY20	FY21E	FY22E	FY23E
Net Debt/ Equity	(0.2)	(0.2)	(0.2)	(0.3)	(0.4
Net Debt/EBIDTA	(0.3)	(0.2)	(0.3)	(0.3)	(0.5
Working Cap Cycle (days)	(29.8)	(17.6)	(19.1)	(18.8)	(19.9
Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	6.6	1.4	4.0	9.8	10.0
EBITDA	11.1	(2.8)	8.4	12.1	11.1
EBIT	12.7	(6.8)	9.4	13.7	11.6
PAT	15.2	5.3	3.9	13.9	11.9
Quarterly (Rs mn)	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20
	041113			11,472	10,713
	11 520	10 0/0			
Revenue	11,538	10,849	12,218		
Revenue EBITDA	3,104	2,998	3,230	3,161	2,629
Revenue EBITDA EBITDA Margin (%)	3,104 <b>26.9</b>	2,998 <b>27.6</b>	3,230 <b>26.4</b>	3,161 <b>27.6</b>	2,629 <b>24.</b>
Revenue EBITDA EBITDA Margin (%) PAT	3,104 <b>26.9</b> 1,976	2,998 <b>27.6</b> 1,691	3,230 <b>26.4</b> 2,441	3,161 <b>27.6</b> 1,991	2,629 <b>24.5</b> 2,042
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs)	3,104 <b>26.9</b>	2,998 <b>27.6</b>	3,230 <b>26.4</b>	3,161 <b>27.6</b>	2,629 <b>24.5</b> 2,042
Revenue EBITDA EBITDA Margin (%) PAT	3,104 <b>26.9</b> 1,976	2,998 <b>27.6</b> 1,691	3,230 <b>26.4</b> 2,441	3,161 <b>27.6</b> 1,991	2,629 <b>24.</b>
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research	3,104 <b>26.9</b> 1,976 <b>7.3</b>	2,998 27.6 1,691 6.2	3,230 <b>26.4</b> 2,441 <b>9.0</b>	3,161 <b>27.6</b> 1,991 <b>7.3</b>	2,629 <b>24.</b> 2,042 <b>7.</b>
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%)	3,104 26.9 1,976 7.3 Mar-19	2,998 27.6 1,691 6.2 Jun-19	3,230 26.4 2,441 9.0 Sep-19	3,161 27.6 1,991 7.3 Dec-19	2,629 24.5 2,042 7.5 Mar-20 51.0
Revenue EBITDA EBITDA Margin (%) PAT EPS (Rs) Source: Company, Emkay Research Shareholding Pattern (%) Promoters	3,104 26.9 1,976 7.3 <u>Mar-19</u> 51.0	2,998 27.6 1,691 6.2 Jun-19 51.0	3,230 26.4 2,441 9.0 Sep-19 51.0	3,161 27.6 1,991 7.3 Dec-19 51.0	2,629 24.9 2,042 7.9 Mar-20

Source: Capitaline

# RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
14-Apr-20	1,357	1,450	12m	Buy	Ashit Desai
31-Jan-20	1,329	1,620	12m	Buy	Ashit Desai
25-Dec-19	1,474	1,720	12m	Buy	Ashit Desai
24-Oct-19	1,564	1,720	12m	Buy	Ashit Desai
20-Sep-19	1,397	1,610	12m	Buy	Ashit Desai
14-Sep-19	1,254	1,370	12m	Hold	Ashit Desai
18-Jul-19	1,204	1,240	12m	Hold	Ashit Desai
27-May-19	1,180	1,240	12m	Hold	Ashit Desai
09-Apr-19	1,231	1,240	12m	Hold	Ashit Desai
24-Jan-19	1,322	1,240	12m	Hold	Ashit Desai
30-Oct-18	1,100	1,200	12m	Hold	Ashit Desai
27-Jul-18	1,103	1,200	12m	Hold	Ashit Desai
21-May-18	1,208	1,230	12m	Hold	Ashit Desai
16-Oct-17	1,063	1,108	12m	Hold	Amit Purohit

Source: Company, Emkay Research

**RECOMMENDATION HISTORY CHART** 



Source: Bloomberg, Company, Emkay Research



Analyst: Ashit Desai

#### **Contact Details**

ashit.desai@emkayglobal.com

+91 22 6612 1340

#### Sector

Consumer Goods & Retail

#### Analyst bio

Ashit Desai holds a PGDM and FRM (US GARP) with 12 years of research experience on the sell side. His team currently covers 24 stocks in the Indian Consumer and Retail space.

# Emkay Alpha Portfolio – Consumer Goods & Retail

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Consumer Goods & Retail	14.14	14.14	0%	0	100.00
Asian Paints	1.46	0.65	-55%	-81	4.61
Berger Paints	0.23	0.00	-100%	-23	0.00
Britannia Industries	0.75	1.08	44%	33	7.66
Colgate-Palmolive	0.37	0.52	42%	15	3.68
Dabur India	0.51	0.61	19%	10	4.29
Emami	0.09	0.00	-100%	-9	0.00
Godrej Consumer Products	0.45	0.00	-100%	-45	0.00
Hindustan Unilever	3.61	3.08	-15%	-53	21.78
ITC	3.31	3.72	13%	42	26.33
Marico	0.34	0.32	-5%	-2	2.26
Nestle India	1.19	0.95	-20%	-24	6.75
Pidilite Industries	0.45	0.00	-100%	-45	0.00
Radico Khaitan	0.00	0.30	NA	30	2.12
United Breweries	0.13	0.72	450%	59	5.08
United Spirits	0.00	0.50	NA	50	3.56
ABFRL	0.07	0.29	302%	22	2.07
Jubilant FoodWorks	0.24	0.44	83%	20	3.14
Page Industries	0.22	0.00	-100%	-22	0.00
Shoppers Stop	0.00	0.00	NA	0	0.00
Titan Company	0.73	0.94	29%	21	6.66
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research

\* Not under coverage: Equal Weight


High Conviction/Strong Over Weight

#### Sector portfolio NAV

	Base					Latest
	1-Apr-19	20-Aug-19	21-Nov-19	20-Feb-20	21-Apr-20	21-May-20
EAP - Consumer Goods & Retail	100.0	97.7	107.0	111.4	98.6	95.6
BSE200 Neutral Weighted Portfolio (ETF)	100.0	94.6	101.4	104.2	94.6	90.5

\*Performance measurement base date 1<sup>st</sup> April 2019 Source: Emkay Research

#### **NAV chart**



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): SMID

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

# **Emkay Rating Distribution**

BUY Over 15%	
HOLD Between -5% to 15%	
SELL Below -5%	

Completed Date: 23 May 2020 02:12:31 (SGT) Dissemination Date: 23 May 2020 02:13:31 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of May 22, 2020
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of May 22, 2020.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 22, 2020
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the May 22, 2020

RESTRICTIONS ON D	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

# Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com